A Phase 2 interventional study of nilotinib in Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 62 sites in 18 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 16th largest by enrollment, is one of 6 that started in 2012, is one of 25 in phase 2, and was the 35th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 22nd largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2012, is one of 19 in phase 2, and was the 47th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib (Gleevec) when they were first diagnosed with CML, then switched to nilotinib (Tasigna) for at least 2 years with the combined time on imatinib (Gleevec) and nilotinib (Tasigna) for at least 3 years and have very small amount of leukemia cells remaining after the nilotinib (Tasigna) treatment will qualify for the study.
The Primary objective was to evaluate the percentage of patients in TFR within 48 weeks following nilotinib cessation.
This study originally consisted of seven phases (five treatment phases and two treatment-free phases) from which two were the focus of this primary analysis report (consolidation, TFR and treatment re-initiation) The study consisted of 2 main phases: Consolidation and TFR
Nilotinib treatment consolidation phase (NTCS): Patients who satisfied all inclusion/exclusion criteria were enrolled in the consolidation phase and continued to receive nilotinib for 52 weeks at the dose which the patient was receiving prior to study entry. If a patient maintained MR4.5 throughout the consolidation phase, he/she was eligible to enter in the TFR phase. If a patient had confirmed loss of MR4.5 during the consolidation phase, he/she was not eligible to enter in the TFR phase and continued nilotinib treatment.
Nilotinib TFR phase: Patients who were eligible to enter in the TFR phase after completing the 52 week consolidation phase stopped taking nilotinib on the first day of the TFR phase. Duration of this phase was up to 520 weeks after the last patient enters in the TFR phase.
Nilotinib treatment re-initiation phase (NTRI): If a patient had a confirmed loss of MR4 (two consecutive BCR-ABL >0.01% IS) or loss of MMR (BCR-ABL >0.1% IS) in the TFR phase, the patient restarted nilotinib treatment. Patients will be on nilotinib treatment for up to 520 weeks after the last patient entered the nilotinib TFR phase, or until a patient experience unacceptable toxicity, disease progression and/or treatment discontinued at the discretion of the Investigator or if the patient withdrew consent. Nilotinib cessation was not attempted for a second time in the patient who reinitiated treatment or discontinued following the TFR phase.
Nilotinib treatment continuation phase (NTCT) and Nilotinib treatment prolonged continuation phase (NTCT-P): Patients who were not eligible to enter into the TFR phase after completing the 52-week NTCS phase entered the nilotinib treatment continuation (NTCT) phase and would continue treatment with nilotinib for another 52 weeks (a total of 104 weeks of treatment). Patients who were not able to maintain MR4.5 and had a confirmed loss of MR4.5 during the NTCT phase were not eligible to enter the TFR-2 phase. These patients entered into the nilotinib prolonged treatment continuation phase (NTCT-P) and continued nilotinib treatment until 520 weeks after the last patient entered the nilotinib TFR phase, or until the patients experience unacceptable toxicity, disease progression and/or treatment would be discontinued at the discretion of the Investigator or withdrawal of consent.
Nilotinib TFR-2 phase: Patients who maintained MR4.5 during the NTCT phase were eligible to cease nilotinib treatment and enter the TFR-2 phase. The duration of the nilotinib TFR-2 phase is up to 520 weeks after the last patient entered the TFR phase. Patients stopped taking nilotinib therapy on the day they entered the TFR-2 phase.
Nilotinib treatment re-initiation-2 (NTRI-2): If a patient had a loss of MMR or a confirmed loss of MR4 during the TFR-2 phase, he/she entered the nilotinib treatment re-initiation-2 (NTRI-2) phase and resumed nilotinib treatment at a dose of either 300 mg or 400 mg bid.
Safety follow-up was performed within 30 days after the last dose of study treatment or the last day in TFR/TFR-2.
Post-treatment follow-up visits were performed every 12 weeks up to 520 weeks after the last patient entered the nilotinib TFR phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate end organ function as defined by:
Patients must have the following electrolyte values ≥ LLN (lower limit of normal) limits or corrected to within normal limits with supplements prior to the first dose of study medication:
Patients must have normal marrow function as defined below:
Exclusion Criteria:
Known impaired cardiac function including any one of the following:
Women of , defined as all women physiologically capable of becoming pregnant, must have a negative serum pregnancy test before initiation of study treatment and must also use highly effective methods of while enrolled in the study. The use of highly effective contraception should continue for at least 14 days after the last dose of study treatment or until the last day of TFR/TFR-2, or for the duration of a monthly cycle of oral contraception, whichever is longer. Acceptable forms of highly effective contraception methods include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with minimum 3 years of tyrosine kinase inhibitor treatment (first with imatinib and then switched to nilotinib) since initial diagnosis, at least 2 years of nilotinib treatment prior to study entry and who achieved MR4.5 (local laboratory assessment) during nilotinib treatment, and determined by a Novartis designated central PCR lab assessment at screening
Drug: nilotinib
Nilotinib was dosed by weight or body surface area. Nilotinib 300 mg BID or 400 mg BID was be administered orally at approximately 12 hour intervals, and must not have been taken with food. The capsules were to be swallowed whole with water. No food should have been consumed for at least 2 hours before the dose was taken and no additional food should have been consumed for at least one hour after the dose was taken. Patients were also allowed to enter this study on the same dose they were taking prior to study entry. Patients who required permanent dose reduction from their original starting dose were to be allowed to enter this study on the same dose only if the patient maintained this dose for a minimum of 6 months prior to study entry.
Also known as: AMN107
Percentage of Participants in TFR Within 48-weeks Following Nilotinib Cessation
TFR is defined as no confirmed loss of MR4 (Molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \> 0.01% IS. Loss of MMR does not require confirmation.
Time frame: first 48 weeks following nilotinib cessation
Percentage of Participants in TFR Within 96, 144, 192, 264 Weeks, and Within the End of Years 6, 7, 8, 9 and 10 Following Nilotinib Cessation
TFR is defined as no confirmed loss of MR4 (molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \> 0.01% IS. Loss of MMR does not require confirmation.
Time frame: first 96, 144, 192, 264 weeks, and within the end of years 6, 7, 8, 9 and 10 following nilotinib cessation.
Progression Free Survival (PFS) After the Start of the TFR Phase
Progression free survival, defined as the time from the date of start of TFR to the date of event defined as the first occurrence of documented disease progression to Accelerated phase/Blast Crises (AP/BC) or the date of death from any cause.
Time frame: nilotinib cessation up to approximately 580 weeks
Treatment Free Survival (TFS) After the Start of the TFR Phase
Treatment-free survival defined as the time from the date of start of TFR to the date of earliest occurrence of any of the following events: loss of MMR, confirmed loss of MR4, re-initiation of nilotinib treatment due to any cause, progression to acute phase (AP) or blast crisis (BC) or death due to any cause.
Time frame: nilotinib cessation up to approximately 580 weeks
Overall Survival (OS) After the Start of the TFR Phase
Overall survival, defined as the time from start date of TFR (date of entering the TFR phase) to date of death due to any cause at any time during the study, including the follow-up period after discontinuation of study up to LPLV. If a patient is not known to have died, survival will be censored at the date of last contact.
Time frame: nilotinib cessation up to approximately 580 weeks
BCR-ABL Ratio (%) Over Time in Nilotinib Treatment Re-initiation Phase (NTRI)
ABL= Abelson leukemia virus and BCR=Break point cluster region. The BCR-ABL ratio (%) represents the level of BCR-ABL fusion gene transcripts relative to a control gene (ABL) measured in peripheral blood samples using quantitative reverse transcription polymerase chain reaction (RT-PCR). Results are expressed as a percentage on the International Scale (IS), a standardized reporting method that allows comparison across laboratories. The BCR-ABL ratio is used to assess the molecular response to treatment, with lower values indicating a reduced disease burden.
Time frame: re-start of nilotinib up to approximately 48 weeks
Percentage of Participants With Stable MMR in Nilotinib Re-initiation Phase
Percentage of participants who were in stable MMR (stable MMR=BCR-ABL ≤ 0.1% IS) at multiple timepoints after achievement of that response in the nilotinib re-initiation phase for those timepoints.
Time frame: at 48 weeks, 96 weeks, 144 weeks, 192 weeks, 240 weeks, 288 weeks, 336 weeks, 384 weeks and 432 weeks after re-initiating Nilotinib in the NTRI Phase
Proportion of Participants With Stable MR4.5 in Nilotinib Re-initiation Phase
Percentage of participants who were in stable MR4.5 (stable MR4.5=BCR-ABL ≤ 0.0032% IS) at multiple time points after achievement of that response in the nilotinib re-initiation phase for those timepoints.
Time frame: at 48 weeks, 96 weeks, 144 weeks, 192 weeks, 240 weeks, 288 weeks, 336 weeks, 384 weeks and 432 weeks
Percentage of Participants With Stable MR4 in Nilotinib Re-initiation Phase
Percentage of participants who were in stable MR4 (stable MR4=BCR-ABL ≤ 0.01% IS) at multiple timepoints after achievement of that response in the nilotinib re-initiation phase for those timepoints.
Time frame: at 48 weeks, 96 weeks, 144 weeks, 192 weeks, 240 weeks, 288 weeks, 336 weeks, 384 weeks and 432 weeks
Recruitment for the study comprised a total of 163 participants, who were enrolled at 63 clinical sites distributed across 18 different countries.. Argentina (2), Australia (3), Belgium (1), Brazil (6), Canada (4), France (5), Germany (5), Greece (3), Israel (3), Japan (7), Mexico (1), Poland (3), Russia (3), Singapore (1), South Korea (1), Spain (8), UK (2), US (5)
| Milestone | NTCS Phase |
|---|---|
| Started | 163 |
| Tfr phase | 126 |
| Ntri phase | 61 |
| Ntct phase | 26 |
| Tfr-2 phase | 7 |
| Ntri-2 phase | 2 |
| Ntct-p phase | 14 |
| Completed | 152 |
| Not completed | 11 |
| Withdrew: Adverse event | 5 |
| Withdrew: Physician decision | 1 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Subject/guardian decision | 2 |
| Withdrew: Death | 1 |
TFR is defined as no confirmed loss of MR4 (Molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \> 0.01% IS. Loss of MMR does not require confirmation.
| Participants | TFR Phase |
|---|---|
| Percentage of Participants in TFR Within 48-weeks Following Nilotinib Cessation | 73 |
TFR is defined as no confirmed loss of MR4 (molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \> 0.01% IS. Loss of MMR does not require confirmation.
| Participants | TFR Phase |
|---|---|
| Week 96 | 67 |
| Week 144 | 61 |
| Week 192 | 58 |
| Week 264 | 54 |
| Week 312 | 50 |
| Week 360 | 44 |
| Week 408 | 41 |
| Week 468 | 38 |
| Week 528 | 32 |
Progression free survival, defined as the time from the date of start of TFR to the date of event defined as the first occurrence of documented disease progression to Accelerated phase/Blast Crises (AP/BC) or the date of death from any cause.
| Weeks | TFR Phase |
|---|---|
| Progression Free Survival (PFS) After the Start of the TFR Phase | NA (NA to NA) |
Treatment-free survival defined as the time from the date of start of TFR to the date of earliest occurrence of any of the following events: loss of MMR, confirmed loss of MR4, re-initiation of nilotinib treatment due to any cause, progression to acute phase (AP) or blast crisis (BC) or death due to any cause.
| Weeks | TFS Phase |
|---|---|
| Treatment Free Survival (TFS) After the Start of the TFR Phase | 169 (27.9 to NA) |
Overall survival, defined as the time from start date of TFR (date of entering the TFR phase) to date of death due to any cause at any time during the study, including the follow-up period after discontinuation of study up to LPLV. If a patient is not known to have died, survival will be censored at the date of last contact.
| Weeks | TFS Phase |
|---|---|
| Overall Survival (OS) After the Start of the TFR Phase | NA (NA to NA) |
ABL= Abelson leukemia virus and BCR=Break point cluster region. The BCR-ABL ratio (%) represents the level of BCR-ABL fusion gene transcripts relative to a control gene (ABL) measured in peripheral blood samples using quantitative reverse transcription polymerase chain reaction (RT-PCR). Results are expressed as a percentage on the International Scale (IS), a standardized reporting method that allows comparison across laboratories. The BCR-ABL ratio is used to assess the molecular response to treatment, with lower values indicating a reduced disease burden.
| Percent | NTRI Phase |
|---|---|
| Baseline | 1.53342 ± 8.070454 |
| Week 4 | 1.01436 ± 4.354164 |
| Week 8 | 0.44840 ± 2.571063 |
| Week 12 | 0.29952 ± 2.232066 |
| Week 16 | 0.33012 ± 2.481822 |
| Week 20 | 0.18411 ± 1.330561 |
| Week 24 | 0.00377 ± 0.013461 |
| Week 36 | 0.01599 ± 0.106080 |
| Week 48 | 0.02040 ± 0.132190 |
Percentage of participants who were in stable MMR (stable MMR=BCR-ABL ≤ 0.1% IS) at multiple timepoints after achievement of that response in the nilotinib re-initiation phase for those timepoints.
| Participants | NTRI Phase |
|---|---|
| Stable MMR for 48 weeks | 52 |
| Stable MMR for 96 weeks | 46 |
| Stable MMR for 144 weeks | 41 |
| Stable MMR for 192 weeks | 38 |
| Stable MMR for 240 weeks | 31 |
| Stable MMR for 288 weeks | 27 |
| Stable MMR for 336 weeks | 24 |
| Stable MMR for 384 weeks | 22 |
| Stable MMR for 432 weeks [ | 18 |
Percentage of participants who were in stable MR4.5 (stable MR4.5=BCR-ABL ≤ 0.0032% IS) at multiple time points after achievement of that response in the nilotinib re-initiation phase for those timepoints.
| Participants | NTRI Phase |
|---|---|
| Stable MR4.5 for 48 weeks | 46 |
| Stable MR4.5 for 96 weeks | 43 |
| Stable MR4.5 for 144 weeks | 39 |
| Stable MR4.5 for 192 weeks | 35 |
| Stable MR4.5 for 240 weeks | 29 |
| Stable MR4.5 for 288 weeks | 25 |
| Stable MR4.5 for 336 weeks | 23 |
| Stable MR4.5 for 384 weeks | 21 |
| Stable MR4.5 for 432 weeks | 18 |
Percentage of participants who were in stable MR4 (stable MR4=BCR-ABL ≤ 0.01% IS) at multiple timepoints after achievement of that response in the nilotinib re-initiation phase for those timepoints.
| Participants | NTRI Phase |
|---|---|
| Stable MR4 for 48 weeks | 48 |
| Stable MR4 for 96 weeks | 44 |
| Stable MR4 for 144 weeks | 40 |
| Stable MR4 for 192 weeks | 36 |
| Stable MR4 for 240 weeks | 30 |
| Stable MR4 for 288 weeks | 26 |
| Stable MR4 for 336 weeks | 23 |
| Stable MR4 for 384 weeks | 21 |
| Stable MR4 for 432 weeks | 18 |
Collected over Adverse events were monitored/assessed for the following duration for each phase: NTCS: up to 52 weeks, TFR Phase: up to 528 weeks, NTRI Phase: up to 500 weeks, NTCT Phase: up to 48 weeks, TFR-2 Phase: up to 480 weeks, NTRI-2 Phase: up to 460 weeks, NTCT-P Phase: up to 480 weeks; Post-treatment follow up (only deaths monitored/assessed): up to 1 year after end of participation in the study phases.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib Treatment Consolidation (NTCS) Phase | 1/163 (0.6%) | 21/163 (12.9%) | 103/163 (63.2%) |
| Nilotinib Treatment-free Remission (TFR) Phase | 3/126 (2.4%) | 34/126 (27%) | 93/126 (73.8%) |
| Nilotinib Treatment Re-initiation (NTRI) Phase | 1/61 (1.6%) | 27/61 (44.3%) | 56/61 (91.8%) |
| Nilotinib Treatment Continuation (NTCT) Phase | 0/26 (0%) | 3/26 (11.5%) | 19/26 (73.1%) |
| Nilotinib Treatment-free Remission - 2 Phase (TRF-2) | 0/7 (0%) | 3/7 (42.9%) | 6/7 (85.7%) |
| Nilotinib Treatment Re-initiation-2 Phase (NTRI-2) | 0/2 (0%) | 2/2 (100%) | 2/2 (100%) |
| Nilotinib Treatment Prolonged Continuation Phase (NTCT-P) | 0/14 (0%) | 5/14 (35.7%) | 11/14 (78.6%) |
| All Patients | 5/163 (3.1%) | 80/163 (49.1%) | 151/163 (92.6%) |
| Post-treatment Follow-up | 7/71 (9.9%) | — | — |
| Event | Nilotinib Treatment Consolidation (NTCS) Phase | Nilotinib Treatment-free Remission (TFR) Phase | Nilotinib Treatment Re-initiation (NTRI) Phase | Nilotinib Treatment Continuation (NTCT) Phase | Nilotinib Treatment-free Remission - 2 Phase (TRF-2) | Nilotinib Treatment Re-initiation-2 Phase (NTRI-2) | Nilotinib Treatment Prolonged Continuation Phase (NTCT-P) | All Patients | Post-treatment Follow-up |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular disorderCardiac disorders | 0/163 | 0/126 | 0/61 | 0/26 | 0/7 | 1/2 | 0/14 | 1/163 | — |
| Arterial occlusive diseaseVascular disorders | 0/163 | 0/126 | 0/61 | 0/26 | 0/7 | 1/2 | 0/14 | 1/163 | — |
| Inguinal herniaGastrointestinal disorders | 0/163 | 2/126 | 0/61 | 0/26 | 1/7 | 0/2 | 0/14 | 3/163 | — |
| Oedema peripheralGeneral disorders | 0/163 | 0/126 | 0/61 | 0/26 | 1/7 | 0/2 | 0/14 | 1/163 | — |
| Hepatic encephalopathyNervous system disorders | 0/163 | 0/126 | 0/61 | 0/26 | 1/7 | 0/2 | 0/14 | 1/163 | — |
| Duodenal ulcer perforationGastrointestinal disorders | 0/163 | 0/126 | 0/61 | 0/26 | 0/7 | 0/2 | 1/14 | 1/163 | — |
| Urinary tract infectionInfections and infestations | 0/163 | 1/126 | 0/61 | 0/26 | 0/7 | 0/2 | 1/14 | 2/163 | — |
| Spinal stenosisMusculoskeletal and connective tissue disorders | 0/163 | 0/126 | 1/61 | 0/26 | 0/7 | 0/2 | 1/14 | 2/163 | — |
| Thrombotic strokeNervous system disorders | 0/163 | 0/126 | 0/61 | 0/26 | 0/7 | 0/2 | 1/14 | 1/163 | — |
| IgA nephropathyRenal and urinary disorders | 0/163 | 0/126 | 0/61 | 0/26 | 0/7 | 0/2 | 1/14 | 1/163 | — |
| Event | Nilotinib Treatment Consolidation (NTCS) Phase | Nilotinib Treatment-free Remission (TFR) Phase | Nilotinib Treatment Re-initiation (NTRI) Phase | Nilotinib Treatment Continuation (NTCT) Phase | Nilotinib Treatment-free Remission - 2 Phase (TRF-2) | Nilotinib Treatment Re-initiation-2 Phase (NTRI-2) | Nilotinib Treatment Prolonged Continuation Phase (NTCT-P) | All Patients | Post-treatment Follow-up |
|---|---|---|---|---|---|---|---|---|---|
| Staphylococcal infectionInfections and infestations | 0/163 | 0/126 | 0/61 | 0/26 | 0/7 | 1/2 | 0/14 | 1/163 | — |
| Procedural painInjury, poisoning and procedural complications | 0/163 | 1/126 | 2/61 | 0/26 | 1/7 | 1/2 | 0/14 | 5/163 | — |
| HyperglycaemiaMetabolism and nutrition disorders | 1/163 | 5/126 | 11/61 | 1/26 | 1/7 | 1/2 | 1/14 | 18/163 | — |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 1/163 | 2/126 | 6/61 | 0/26 | 2/7 | 1/2 | 1/14 | 10/163 | — |
| HypervolaemiaMetabolism and nutrition disorders | 0/163 | 0/126 | 0/61 | 0/26 | 0/7 | 1/2 | 0/14 | 1/163 | — |
| AngiopathyVascular disorders | 0/163 | 0/126 | 0/61 | 0/26 | 0/7 | 1/2 | 0/14 | 1/163 | — |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/163 | 43/126 | 12/61 | 2/26 | 0/7 | 0/2 | 1/14 | 62/163 | — |
| HypertensionVascular disorders | 13/163 | 23/126 | 19/61 | 1/26 | 1/7 | 0/2 | 2/14 | 50/163 | — |
| COVID-19Infections and infestations | 0/163 | 11/126 | 4/61 | 0/26 | 1/7 | 0/2 | 4/14 | 20/163 | — |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/163 | 22/126 | 4/61 | 0/26 | 2/7 | 0/2 | 1/14 | 32/163 | — |
| Age, Continuous(years) | NTCS Phase |
|---|---|
| Mean | 54.3 ± 13.99 |
| Sex: Female, Male(Participants) | NTCS Phase |
|---|---|
| Female | 86 |
| Male | 77 |
| Race/Ethnicity, Customized(participants) | NTCS Phase |
|---|---|
| Caucasian | 127 |
| Black | 6 |
| Asian | 23 |
| Native American | 1 |
| Other | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2012 to primary completion in Nov 2015, 35 months.
Results were first posted in Jan 2021, 5 years 1 month after primary completion.
Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 35 months is below that.
Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →